Lower GI Series Market Research Report Information: By Applications (Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis and others), By Test Types (Double-Contrast and Single-Contrast) and By End Users (Hospitals, Clinics & Laboratories) - Global Forecast till 2032

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6. Global Lower GI Series Market, by Applications

6.1 Gastroenteritis

6.2 Colon polyps

6.3 Tumor

6.4 Strictures Crohn's disease

6.5 Ulcerative colitis

6.6 Others

7. Global Lower GI Series Market, by Type of Test

7.1 Double-contrast

7.2 Single-contrast

8 Global Lower GI Series Market, by End Users

8.1 Hospitals

8.2 Clinics & laboratories

9. Global Point of Care Technology Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 UK

9.3.1.3 France

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Cost of Products

10.2 Production Capacity of Major Players

11 Company Profile

11.1 Eisai (US)

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Cadila Pharmaceuticals

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Purdue Pharma L.P

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Development

11.4 PeaceHealth

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Development

11.5 Alfa Wassermann

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 NOVADAQ

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 AstraZeneca

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Developments

11.8 Ironwood Pharmaceuticals

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Updates

11.8.4 Key Developments

11.9 Others

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Updates

11.9.4 Key Developments

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Gastro-care Industry

13 Appendix